Management of gynaecological cancers

Quality in Health Care

Volumn 8, Issue 4, 1999, Pages 270-279

  Melville, Arabella ^a,c   Eastwood, Alison ^a   Kleijnen, Jos ^a   Kitchener, Henry ^b   Martin Hirsch, Pierre ^b   Nelson, Linsey ^b  

^a UNIVERSITY OF YORK   (United Kingdom)

^b ST MARY S HOSPITAL   (United Kingdom)

^c NONE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; HYDROXYUREA; PACLITAXEL;

CANCER PALLIATIVE THERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG INDUCED DISEASE; ENDOMETRIUM CANCER; FEMALE; GYNECOLOGIC CANCER; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; MULTIMODALITY CANCER THERAPY; OVARY CANCER; RANDOMIZED CONTROLLED TRIAL; REVIEW; UTERINE CERVIX CANCER;

EID: 0346406810     PISSN: 09638172     EISSN: None     Source Type: Journal    
DOI: 10.1136/qshc.8.4.270     Document Type: Review

References (178)

1. Anonymous. Management of gynaecological cancers. York: University of York, NHS Centre for Reviews and Dissemination, 1999.
2. National Cancer Guidance Steering Group. Improving outcomes in gynaecological cancers: the research evidence. London: NHS Executive, Department of Health, 1999.
3. National Cancer Guidance Steering Group. Improving outcomes in gynaecological cancers: the manual. London: NHS Executive, Department of Health, 1999.
4. Office for National Statistics. Data provided on request, 1998.
5. Junor EJ, Hole DJ, Gillis CR. Management of ovarian cancer: referral to a multidisciplinary team matters. Br J Cancer 1994;70:363-70.
6. Junor E, Hole D. Specialist gynaecologists and survival outcome in ovarian cancer: a Scottish National Study of 1866 patients. (in press).
7. Kehoe S, Powell J, Wilson S, et al. The influence of the operating surgeon's specialisation on patient survival in ovarian carcinoma. Br J Cancer 1994;70:1014-7.
8. Nguyen HN, Averette HE, Hoskins W, et al. National survey of ovarian carcinoma: part V. Cancer 1993;72:3663-70.
9. Mayer AR, Chambers SK, Graves E, et al. Ovarian cancer staging: does it require a gynecologic oncologist? Gynecol Oncol 1992;47:223-7.
10. Grant PT, Beischer NA, Planner RS. The treatment of gynaecological malignancy in a general public hospital. Med J Aust 1992;157:378-80.
11. McGowan L. Patterns of care in carcinoma of the ovary. Cancer 1993;71:628-33.
12. Wolfe CD, Tilling K, Bourne HM, et al. Variations in the screening history and appropriateness of management of cervical cancer in South East England. Eur J Cancer 1996; 32A:1198-1204.
13. Begg C, Cramer L, Hoskins W, et al. Impact of hospital volume on operative mortality for major cancer surgery. JAMA 1998;280:1747-51.
14. Woodman C, Baghdady A, Collins S, et al. What changes in the organisation of cancer services will improve the outcome for women with ovarian cancer? Br J Obstet Gynaecol 1997;104:135-9.
15. Wolfe CD, Tilling K, Raju KS. Management and survival of ovarian cancer patients in south east England. Eur J Cancer 1997;33:1835-40.
16. Gills CR, Hole DJ, Still RM, et al. Medical audit, cancer registration, and survival in ovarian cancer. Lancet 1991; 337:611-2.
17. Tilling K, Wolfe CD, Raju KS. Variations in the management and survival of women with endometrial cancer in south east England. Eur J Gynaecol Oncol 1998;19:64-8.
18. Hogberg T, Carstensen J, Simonsen E. Treatment results and prognostic factors in a population-based study of epithelial ovarian cancer. Gynecol Oncol 1993;48:38-49.
19. Munoz KA, Harlan LC, Trimble EL. Patterns of care for women with ovarian cancer in the United States. J Clin Oncol 1997;15:3408-15.
20. Cull A, Cowie VJ, Farquharson DI, et al. Early stage cervical cancer: psychosocial and sexual outcomes of treatment. Br J Cancer 1993;68:1216-20.
21. Cain EN, Kohorn EI, Quinlan DM, et al. Psychological reactions to the diagnosis of gynecologic cancer. Obstet Gynecol 1983;62:635-41.
22. Corney RH, Crowther ME, Everett H, et al. Psychosexual dysfunction in women with gynaecological cancer following radical pelvic surgery. Br J Obstet Gynaecol 1993;100: 73-8.
23. Abitol MM, Davenport JH. Sexual dysfunction after therapy for cervical carcinoma. Am J Obstet Gynecol 1974;119:181-9.
24. Siebel MM, Freeman M, Graves W. Sexual function after surgical and radiation therapy for cervical carcinoma. South Med J 1982;75:1195-7.
25. Carlsson ME, Strang PM. Educational group support for patients with gynaecological cancer and their families. Support Care Cancer 1996;4:102-9.
26. Corney R, Everett H, Howells A, et al. The care of patients undergoing surgery for gynaecological cancer: the need for information, emotional support and counselling. J Adv Nurs 1992;17:667-71.
27. Karani D, Wiltshaw E. How well informed?⋯ new patients with ovarian cancer. Cancer Nurs 1986;9:238-42.
28. Berner ES, Partridge EE, Baum SK. The effects of the PDQ patient information file (PIF) on patients' knowledge, enrollment in clinical trials, and satisfaction. J Cancer Educ 1997;12:121-5.
29. Cancer Guidance Sub-group of the Clinical Outcomes Group. Improving outcomes in breast cancer: the research evidence. London: NHS Executive, Department of Health, 1996.
30. Cancer Guidance Sub-Group of the Clinical Outcomes Group. Improving outcomes in colorectal cancer: the research evidence. London: NHS Executive, Department of Health, 1997.
31. National Cancer Guidance Group. Improving outcomes in lung cancer: the research evidence. London: NHS Executive, Department of Health, 1998.
32. Elit LM, Levine MN, Gafni A, et al. Patients' preferences for therapy in advanced epithelial ovarian cancer: development, testing, and application of a bedside decision instrument. Gynecol Oncol 1996;62:329-35.
33. Mohide EA, Whelan TJ, Rath D, et al. A randomised trial of two information packages distributed to new cancer patients before their initial appointment at a regional cancer centre. Br J Cancer 1996;73:1588-1593.
34. Cain EN, Kohorn EI, Quinlan DM, et al. Psychosocial benefits of a cancer support group. Cancer 1986;57:183-9.
35. Robinson JW, Scott CB, Faris PD. Sexual rehabilitation for women with gynecological cancer: Information is not sufficient. Canadian Journal of Human Sexuality 1994;3:131-42.
36. Capone MA, Good RS, Westie KS, et al. Psychosocial rehabilitation of gynecologic oncology patients. Arch Phys Med Rehabil 1980;61:128-32.
37. Bell R, Petticrew M, Sheldon T. The performance of screening tests for ovarian cancer: results of a systematic review. Br J Obstet Gynaecol 1998;105:1136-47.
38. Jacobs IJ, Skates SJ, MacDonald N, et al. A pilot randomised controlled trial of ovarian cancer screening. Lancet 1999;353:1207-10.
39. Stratton JF, Phaioah P, Smith SK, et al. A systematic review and meta-analysis of family history and risk of ovarian cancer. Br J Obstet Gynaecol 1998;105:493-9.
40. Stratton JF, Gayther SA, Russell P, et al. Contribution of BRCAI mutations to ovarian cancer. N Engl J Med 1997;336:1125-30.
41. Flam F, Einhorn N, Sjovall K. Symptomatology of ovarian cancer. Eur J Obstet Gynecol Reprod Biol 1988;27:53-7.
42. Davies AP, Jacobs I, Woolas R, et al. The adnexal mass: benign or malignant? Evaluation of a risk of malignancy index. Br J Obstet Gynaecol 1993;100:927-31.
43. Tingulstad S, Hagen B, Skjeldestad FE, et al. Evaluation of a risk of malignancy index based on serum CA125, ultrasound findings and menopausal status in the preoperative diagnosis of pelvic masses. Br J Obstet Gynaecol 1996;103:826-31.
44. Jacobs I, Oram D, Fairbanks J, et al. A risk of malignancy index incorporating CA125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer. BrJ Obstet Gynaecol 1990;97:922-9.
45. Maggino T, Gadducci A, D'Addario V, et al. Prospective multicentre study on CA125 in postmenopausal pelvic masses. Gynecol Oncol 1994;54:117-23.
46. Botta G, Zarcone R. Trans-vaginal ultrasound examination of ovarian masses in premenopausal women. Eur J Obstet Gynecol 1995;62:37-41.
47. Caruso A, Caforio L, Testa AC, et al. Transvaginal color Doppler ultrasonography in the presurgical characterization of adnexal masses. Gynecol Oncol 1996;63:184-91.
48. Luxman D, Bergman A, Sagi J, et al. The postmenopausal adnexal mass: correlation between ultrasonic and pathologic findings. Obstet Gynecol 1991;77:726-8.
49. Finkler NJ, Benacerraf B, Lavin PT, et al. Comparison of serum CA125, clinical impression, and ultrasound in the preoperative evaluation of ovarian masses. Obstet Gynecol 1988;72:659-63.
50. Franchi M, Beretta P, Ghezzi F, et al. Diagnosis of pelvic masses with transabdominal color Doppler, CA125 and ultrasonography. Acta Obstet Gynecol Scand 1995;74:734-9.
51. Schutter EMJ, Kenemans P, Sohn C, et al. Diagnositc value of pelvic examination ultrasound, and serum CA125 in postmenopausal women with a pelvic mass. Cancer 1994;74:1398-406.
52. Sengoku K, Satoh T, Saitoh S, et al. Evaluation of transvaginal color Doppler sonography transvaginal sonography and CA125 for prediction of ovarian malignancy. Int J Gynecol Obstet 1994;46:39-43.
53. Buy J-N, Ghossain MA, Hugol D, et al. Characterization of adnexal masses: combination of color Doppler and conventional sonography compared with spectral Doppler analysis alone and conventional sonography alone. Am J Roentgenol 1996;166:385-93.
54. Carter J, Saltzman A, Hartenbach E, et al. Flow characteristics in benign and malignant gynecologic tumors using transvaginal color flow doppler. Obstet Gynecol 1994;83: 125-30.
55. Leeners B, Schild RL, Funk A, et al. Colour doppler sonography improves the pre-operative diagnosis of ovarian tumours made using conventional transvaginal sonography. Eur J Obstet Gynecol 1996;64:79-85.
56. Prömpeler HJ, Madjar H, Sauerbrei W. Classification of adnexal tumors by transvaginal color doppler. Gynecol Oncol 1996;61:354-63.
57. Rehn M, Lohmann K, Rempen A. Transvaginal ultrasonography of pelvic masses: evaluation of B-mode technique and doppler ultrasonography. Am J Obstet Gynecol 1996; 175:97-104.
58. Reles A, Wein U, Lichtenegger W. Transvaginal color Doppler sonography and conventional sonography in the preoperative assessment of adnexal masses. J Clin Ultrasound 1997;25:217-25.
59. Schneider VL, Schneider A, Reed KL, et al. Comparison of doppler with two-dimensional sonography and CA125 for prediction of malignancy of pelvic masses. Obstet Gynecol 1993;81:983-8.
60. Stringini FAL, Gadducci A, Del Bravo B, et al. Differential diagnosis of adnexal masses with transvaginal sonography, color flow imaging, and serum CA125 assay in pre- and postmenopausal women. Gynecol Oncol 1996;61:68-72.
61. Timor-Tritsch IE, Lerner JP, Monteagudon A, et al. Transvaginal ultrasonographic characterization of ovarian masses by means of color flow-directed doppler measurements and a morphologic scoring system. Am J Obstet Gynecol 1993;168:909-13.
62. Hunter RW, Alexander ND, Soutter WP. Meta-analysis of surgery in advanced ovarian carcinoma: is maximum cytoreductive surgery an independent determinant of prognosis? Am J Obstet Gynecol 1992;166:504-11.
63. Marsoni S, Torri V, Valsecchi MG, et al. Prognostic factors in advanced epithelial ovarian cancer. Br J Cancer 1990;62: 444-50.
64. Voest EE, Van Houwelingen JC, Neijt JP. A meta-analysis of prognostic factors in advanced ovarian cancer with median survival and overall survival (measured with the log (relative risk)) as main objectives. Eur J Cancer Clin Care 1989;25:711-20.
65. van der Burg ME, van Lent M, Buyse M, et al. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological cancer cooperative group of the European Organization for Research and Treatment of Cancer. N Engl J Med 1995;332:629-34.
66. Redman CW, Warwick J, Luesley DM, et al. Intervention debulking surgery in advanced epithelial ovarian cancer. Br J Obstet Gynaecol 1994;101:142-6.
67. Advanced Ovarian Cancer Trialists' Group. Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials. Br J Cancer 1998;78:1479-87.
68. The ICON Collaborators. ICON2: randomised trial of single-agent carboplatin against three-drug combination of CAP (cyclophosphamide, doxorubicin, and cisplatin) in women with ovarian cancer. Lancet 1998;352:1571-6.
69. McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996;334:1-6.
70. Piccart M, Bertelsen K, Stuart G, et al. Is cisplatin-paclitaxel the standard first-line treatment of advanced ovarian cancer? The EORTC-GCOG, NOCOVA, NCIC CTG and Scottish Intergroup experience. Proc Annu Meet Am Soc Clin Oncol 1997;16:abstract 1258.
71. Stuart G, Bertelsen K, Mangioni C, et al. Updated analysis shows a highly significant overall improved survival for cispiatin-paclitaxel as first line treatment of advanced ovarian cancer: mature results of the EORTC-GCOG, NOCOVA, NCIC CTG and Scottish Intergroup trial. Proc Annu Meet Am Soc Clin Oncol 1998;17:abstract 1394.
72. Muggia FM, Brady PS, Brady MF, et al. Phase III of cisplatin or paclitaxel versus the combination in suboptimal stage III and IV epithlial ovarian cancer: Gynecological Oncology group (GOG) study. Proc Annu Meet Am Soc Clin Oncol 1997;16:abstract 1257.
73. Du Bois A, Richter B, Warm M, et al. Cisplatin/paclitaxel as first line treatment in ovarian cancer. Proc Annu Meet Am Soc Clin Oncol 1998;17:abstract 1395.
74. Neijt JP, Hansen M, Hansen SW, et al. Randomized phase III study in previously untreated epithelial ovarian cancer FIGO stage IIB, IIC, IV, comparing paclitaxel-cisplatin and paclitaxel-carboplatin. Proc Annu Meet Am Soc Clin Oncol 1997;16:abstract 1259.
75. Ozols R, Bundy B, Fowler J, et al. Randomized phase III study of cisplatin (CIS)/paclitaxel (PAC) versus carboplatin (CARBO)/PAC in optimal stage III epithelial ovarian cancer: a gynaecologic oncology group trial (GOG 158). Proceedings of the Annual Meeting of American Society of Clinical Oncology 1999;18:abstract 1373.
76. Knopf K, Brown M, Kohn E. Lack of improvement in survival in patients with relapsed or refractory epithelial ovarian cancer 1980-97. ASCO Proceedings 1386 1998.
77. Markman M, Rothman R, Hakes T, et al. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol 1991;9:389-93.
78. Lorusso V, Catino A, Leone B, et al. Carboplatin plus ifosfamide as salvage treatment of epithelial ovarian cancer: a pilot study. J Clin Oncol 1993;11:1952-6.
79. Kohn EC, Sarosy G, Bicher A, et al. Dose-intense taxol: high response rate in patients with platinum- resistant recurrent ovarian cancer. J Natl Cancer Inst 1994;86:18-24.
80. Einzig AI, Wiernik PH, Sasloff J, et al. Phase II study and long-term follow-up of patients treated with taxol for advanced ovarian adenocarcinoma. J Clin Oncol 1992;10: 1748-53.
81. Thigpen JT, Blessing JA, Ball H, et al. Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a gynecologic oncology group study. J Clin Oncol 1994;12:1748-53.
82. Trimble EL, Adams JD, Vena D, et al. Paclitaxel for platinum-refractory ovarian cancer: results from the first 1,000 patients registered to National Cancer Institute Treatment Referral Center 9103. J Clin Oncol 1993;11: 2405-10.
83. Haller H, Matejcic N, Rukavina B, et al. Transvaginal sonography and hysteroscopy in women with postmenopausal bleeding. Int J Gynecol Obstet 1996;54:155-9.
84. Ben-Yehuda OM, Kim YB, Leuchter RS. Does hysteroscopy improve upon the sensitivity of dilation and curettage in the diagnosis of endometrial hyperplasia or carcinoma? Gynecol Oncol 1998;68:4-7.
85. Smith-Bindman R, Kerlikowske K, Feldstein VA, et al. Endovaginal ultrasound to exclude endometrial cancer and other endometrial abnormalities. JAMA 1998;280:1510-7.
86. Guido RS, Kanbour-Shakir A, Rulin MC, et al. Pipelle endometrial sampling. J Reprod Med 1995;40:553-5.
87. Eddowes HA, Read MD, Codling BW. Pipelle: a more acceptable technique for outpatient endometrial biopsy. Br J Obstet Gynaecol 1990;97:961-2.
88. Kaunitz AM, Masciello A, Ostrowski M, et al. Comparison of endometrial biopsy with the endometrial Pipelle and Vabra aspirator. J Reprod Med 1988;33:427-31.
89. Silver MM, Miles P, Rosa C. Comparison of Novak and Pipelle endometrial biopsy instruments. Obstet Gynecol 1991;78:828-30.
90. Stovall TG, Ling FW, Morgan PL. A prospective, randomized comparison of the Pipelle endometrial sampling device with the Novak curette. Am J Obstet Gynecol 1991;165:1287-9.
91. Rodriguez GC, Yaqub N, King ME. A comparison of the Pipelle device and the Vabra aspirator as measured by endometrial denudation in hysterectomy specimens: the Pipelle device samples significantly less of the endometrial surface than the Vabra aspirator. Am J Obstet Gynecol 1993; 168:55-9.
92. Stovall TG, Solomon SK, Ling FW. Endometrial sampling prior to hysterectomy. Obstet Gynecol 1989;73:405-9.
93. Stiarez RA, Grimes DA, Majmudar B, et al. Diagnostic endometrial aspiration with the Karman Cannula. J Reprod Med 1983;28:41-4.
94. Shaker AG, Anderson M, Kitchener HC. An out-patient approach to the management of post-menopausal bleeding. Br J Obstet Gynaecol 1991;98:488-90.
95. Creasman WT, Morrow CP, Bundy BN, et al. Surgical pathological spread patterns of endometrial cancer. Cancer 1987;60:2035-41.
96. Belloni C, Vigano R, del Maschio A, et al. Magnetic resonance imaging in endometrial carcinoma staging. Gynecol Oncol 1990;37:172-7.
97. Chen SS, Rumancik WM, Spiegel G. Magnetic resonance imaging in stage I endometrial carcinoma. Obstet Gynecol 1990;75:274-7.
98. Hricak H, Rubinstein LV, Gherman GM, et al. MR imaging evaluation of endometrial carcinoma: results of an NCI cooperative study. Radiology 1991;179:829-32.
99. Hricak H, Stern JL, Fisher MR, et al. Endometrial carcinoma staging by MR imaging. Radiology 1987;162: 297-305.
100. Powell MC, Womack C, Buckley J, et al. Pre-operarive magnetic resonance imaging of stage 1 endometrial adenocarcinoma. Br J Obstet Gynaecol 1986;93:353-60.
101. Sironi S, Colombo E, Villa G, et al. Myometrial invasion by endometrial carcinoma: assessment with plain and gadolinium-enhanced MR imaging. Radiology 1992;185: 207-12.
102. Sironi S, Taccagni G, Garancini P, et al. Myometrial invasion by endometrial carcinoma: assessment by MR imaging. Am J Roentgenol 1992;158:565-9.
103. Yamashita Y, Harada M, Sawada T, et al. Normal uterus and FIGO stage I endometrial carcinoma: dynamic gadolinium-enhanced MR imaging. Radiology 1993;186: 495-501.
104. DelMaschio A, Vanzulli A, Sironi S, et al. Estimating the depth of myometrial involvement by endometrial carcinoma: efficacy of transvaginal sonography vs MR imaging. Am J Roentgenol 1993;160:533-8.
105. Gordon AN, Fleischer AC, Dudley BS, et al. Preoperative assessment of myometrial invasion of endometrial adenocarcinoma by sonography (US) and magnetic resonance imaging (MRI). Gynecol Oncol 1989;34:175-9.
106. Kim SH, Kim HD, Song YS, Kang SB, Lee HP. Detection of deep myometrial invasion in endometrial carcinoma: comparison of transvaginal ultrasound, CT, and MRI. J Comput Assist Tomogr 1995;19:766-72.
107. Thorvinger B, Gudmundsson T, Horvath G, et al. Staging in local endometrial carcinoma. Assessment of magnetic resonance and ultrasound examinations. Acta Radiologica 1989;30:525-9.
108. Yamashita Y, Mizutani H, Torashima M, et al. Assessment of myometrial invasion by endometrial carcinoma: transvaginal sonography vs contrast-enhanced MR imaging. Am J Roentgenol 1993;161:595-9.
109. Varpula MJ, Klemi PJ. Staging of uterine endometrial carcinoma with ultra-low field (0.02 T) MRI: a comparative study with CT. J Comput Assist Tomogr 1993;17:641-7.
110. Berrino F, Sant M, Verdecchia A, et al, editors. Survival of cancer patients in Europe: the EUROCARE study. Lyon: International Agency for Research on Cancer, 1995.
111. Northern and Yorkshire Cancer Registry and Information Service. Unpublished data, 1998.
112. Kilgore LC, Partridge EE, Alvarez RD, et al. Adenocarcinoma of the endometrium: survival comparisons of patients with and without pelvic node sampling. Gynecol Oncol 1995;56:29-33.
113. Medical Research Council Protocol. ASTEC: a study in the treatment of endometrial cancer: A randomised trial of lymphadenectomy and of adjuvant external beam radiotherapy in the treatment of endometrial cancer. London: MRC, 1998.
114. The Swedish Council on Technology Assessment in Health Care. Radiotherapy for cancer. Volume 2: a critical review of the literature. Acta Oncol 1996;Supplementum 7.
115. Aalders J, Abeler V, Kolstad P, et al. Postoperative external irradiation and prognostic parameters in stage I endometrial carcinoma: clinical and histopathologic study of 540 patients. Obstet Gynaecol 1980;56:419-27.
116. Creutzberg CL, van Putten W, Koper P, et al. Postoperative radiotherapy in stage I endometrial carcinoma: results from a prospective randomized trial of 715 patients. ESTRO abstract 307, 1998.
117. Martin-Hirsch PL, Lilford RJ, Jarvis, GJ. Adjuvant progestagen therapy for the treatment of endometrial cancer: review and meta-analyses of published randomised controlled trials. Eur J Obstet Gynecol Reprod Biol 1996;65: 201-7.
118. COSA-NZ-UK Endometrial Cancer Study Groups. Adjuvant medroxyprogesterone acetate in high-risk endometrial cancer. Int J Gynecol Cancer 1998;8:387-91.
119. Scheidler J, Hricak H, Yu KK, et al. Radiological evaluation of lymph node metastases in patients with cervical cancer. A meta-analysis. JAMA 1997;278:1096-101.
120. Innocenti P, Pulli F, Savino L, et al. Staging of cervical cancer: reliability of transrectal US. Radiology 1992;185: 201-5.
121. Deo SV, Shukla NK, Sandhu M, et al. Role of transabdominal pelvic ultrasound and computed tomography in the detection of bladder involvement in advanced cancer of the cervix. Australas Radiol 1996;40:218-20.
122. Landoni F, Maneo A, Colombo A, et al. Randomised study of radical surgery versus radiotherapy for stage Ib- IIa cervical cancer. Lancet 1997;350:535-40.
123. Coyle CA, Davidson SE, Swindel R, et al. A review of patients referred for post-operative radiotherapy following surgery for carcinoma of the cervix in the North West Region. (submitted for publication).
124. Jackson S, Murdoch J, Howe K, et al. The management of cervical carcinoma within the South West Region of England. Br J Obstet Gynaecol 1997;104:140-4.
125. Averrette HE, Ford JH, Dudan RC. Staging of cervical cancer. Clin Obstet Gynecol 1975;18:215.
126. Boyce, Fruchter R, Nicastri AD, et al. Prognostic factors in stage I carcinoma of the cervix. Gynecol Oncol 1981;12: 154-165.
127. Gauthier P, Gore I, Shingleton HM. Identification of histopathologic risk groups in stage Ib squamous cell carcinoma of the cervix. Obstet Gynecol 1985;66:569.
128. Green T. Ureteral suspension for prevention of ureteral complications following radical Wertheim hysterectomy. Obstet Gynecol 1966;28:1-11.
129. Inoue T. Prognostic significance of the depth of invasion relating to nodal metastases, parametrial extension, and cell types. Cancer 1984;54:3035-42.
130. Lagasse LD, Ballon SC, Berman ML, et al. Pretreatment lymphangiography and operative evaluation in carcinoma of the cervix. Am J Obstet Gynecol 1979;134:219.
131. Larson G, Alm P, Gullberg B, et al. Prognostic factors in early invasive carcinoma of the uterine cervix. Am J Obstet Gynecol 1983;146:145.
132. Lohe KJ. Early squamous cell carcinoma of the uterine cervix. Gynecol Oncol 1978;6:10-30.
133. Morrow P. Panel report: Is pelvic radiation beneficial in the postoperative management of stage Ib squamous cell carcinoma of the cervix with pelvic node metastases treated by radical hysterectomy and pelvic lymphadenectomy? Gynecol Oncol 1980;10;105.
134. Nahhas W, Sharkey F, Whitney C. The prognostic significance of vascular channel involvement in deep stromal penetration in early cervical carcinoma. Am J Clin Oncol 1983;6:259.
135. Tinga DJ, Timmer PR, Bouma J, et al. Prognostic significance of single versus multple lymph node metastases in cervical carcinoma Ib. Gynecol Oncol 1990;39:175.
136. Van Nagell J, Donaldson E, Parker J. The prognostic significance of cell type and lesion size in patients with cervical cancer treated by radical surgery. Gynecol Oncol 1977; 5:142.
137. Bissen D, Lamont DW, Nwabineli NJ, et al. The treatment of stage I carcinoma of the cervix in the west of Scotland 1980-1987. Br J Obstet Gynaecol 1994;101:615-20.
138. Morley GW, Seski JC. Radical pelvic surgery versus radiation therapy for stage I carcinoma of the cervix (exclusive of microinvasion). Am J Obstet Gynecol 1976;126:785-98.
139. Newton M, Radical hysterectomy or radiotherapy for stage I cervical cancer. A prospective comparison with 5 and 10 years follow-up. Am J Obstet Gynecol 1975;123:535-42.
140. Patel FD, Sharma SC, Negi PS, et al. Low dose rate vs. high dose rate brachytherapy in the treatment of carcinoma of the uterine cervix: a clinical trial. Int J Radiat Biol Phys 1994;28:335-41.
141. Teshima T, Inoue T, Ikeda H, et al. High-dose rate and low-dose rate intracavitary therapy for carcinoma of the uterine cervix. Final results of Osaka University Hospital. Cancer 1993;72:2409-14.
142. Haie-Meder C, Kramar A, Lambin P, et al. Analysis of complications in a prospective randomized trial comparing two brachytherapy low dose rates in cervical carcinoma. Int J Radiat Oncol Biol Phys 1994;29:953-60.
143. Lambin P, Gerbaulet A, Kramar A, et al. Phase III trial comparing two low dose rates in brachytherapy of cervix carcinoma: report at two years. Int Radiat Oncol Biol Phys 1993;25:405-12.
144. Soisson AP, Soper JT, Clarke-Pearson P, et al. Adjuvant radiotherapy following radical hysterectomy for patients with stage IB and IIA cervical cancer. Gynecol Oncol 1990; 37:390-5.
145. Kinney WK, Alvarez RD, Reid GC, et al. Value of adjuvant whole-pelvis irradiation after Wertheim hysterectomy for early-stage squamous carcinoma of the cervix with pelvic nodal metastasis: a matched-control study. Gynecol Oncol 1989;34:258-62.
146. Rose PG, Bundy BN, Watkins EB, et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med 1999;340:1144-53.
147. Keys HM, Bundy BN, Stehman FB, et al. Cisplatin, radiation and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med 1999;340:1154-61.
148. Morris M, Eifel PJ, Lu J, et al. Pelvic radiation with concurrent chemotherapy versus pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med 1999; 340:1137-43.
149. Peters WA, Liu PY, Barrett RJ, et al. Cisplatin and 5-fluorouracil plus radiation therapy are superior to radiation therapy as adjunctive in high-risk early-stage carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy: report of a phase III intergroup study, (in press).
150. Whitney CW, Sause W, Bundy BN, et al. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stages IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes. A gynecologic oncology group and southwest oncology group study. J Clin Oncol 1999;17:1339-48.
151. Chauvergne J, Lhomme C, Rohart J, et al. [Neoadjuvant chemotherapy of stage IIb or III cancers of the uterine cervix. Long-term results of a multicenter randomized trial of 151 patients]. Bull Cancer 1993;80:1069-79.
152. Chiara S, Bruzzone M, Merlini L, et al. Randomized study comparing chemotherapy plus radiotherapy versus radiotherapy alone in FIGO stage IIB-III cervical carcinoma. GONO (North-West Oncologic Cooperative Group). Am J Clin Oncol 1994;17:294-7.
153. Kumar L, Pokharel YH, Grover GK, et al. Neoadjuvant chemotherapy (CT) followed by radiotherapy (RT) in locally advanced squamous cell cervical cancer (SCC): two randomised studies. Proc Annu Meet Am Soc Clin Oncol 1997;16:abstract 1295.
154. Sardi J, Sananes C, Giaroli A, et al. Neoadjuvant chemotherapy in squamous cervical carcinoma stage IIIb. Gynecol Oncol 1994;52:104 (abstract 10).
155. Sardi JE, Giaroli A, Sananes C, et al. Long-term follow-up of the first randomized trial using neoadjuvant chemotherapy in stage Ib squamous carcinoma of the cervix: the final results. Gynecol Oncol 1997;67:61-9.
156. Souhami L, Gil RA, Allan SE, et al. A randomized trial of chemotherapy followed by pelvic radiation therapy in stage IIIB carcinoma of the cervix. J Clin Oncol 1991;9:970-7.
157. Sundfor K, Trope CG, Hogberg T, et al. Radiotherapy and neoadjuvant chemotherapy for cervical carcinoma. A randomized multicenter study of sequential cisplatin and 5-fluorouracil and radiotherapy in advanced cervical carcinoma stage 3B and 4A. Cancer 1996;77:2371-8.
158. Symonds RP, Cowie V, E. DS, et al. The Scottish and Manchester randomised trial of neoadjuvant chemotherapy for advanced cervical cancer. Int J Gynecol Cancer 1997;7:{suppl 2) abstract 050.
159. Tattersall MHN, Ramirez C, Coppleson M. A randomized trial comparing platinum-based chemotherapy followed by radiotherapy alone in patients with locally advanced cervical cancer. Int J Gynecol Cancer 1992;2:244-51.
160. Tattersall MH, Lorvidhaya V, Vootiprux V, et al. Randomized trial of epirubicin and cisplatin chemotherapy followed by pelvic radiation in locally advanced cervical cancer. Cervical cancer study group of the Asian Oceanian Clinical Oncology Association. J Clin Oncol 1995;13:444-51.
161. Tierney JF, Stewart LA, Parmar MKB. Can the published data tell us about the effectiveness of neoadjuvant chemotherapy for locally advanced cancer of the uterine cervix? Eur J Cancer 1999;35:406-9.
162. Robertson G, Lopes A, Beynon G, et al. Pelvic exenteration: a review of the Gateshead experience 1974-1992. Br J Obstet Gynaecol 1994;101:529-31.
163. Shepherd JH, Ngan HYS, Neven P, et al. Multivariate analysis of factors affecting survival in pelvic exenteration. Int J Gynecol Cancer 1994;4:361-70.
164. Morley GW, Hopkins MP, Lindenauer SM, et al. Pelvic exenteration, University of Michigan: 100 patients at 5 years. Obstet Gynecol 1989;74:934-43.
165. Kerr-Wilson RH, McCrum A. Follow-up of patients with gynaecological cancer. Aust N Z J Obstet Gynaecol 1995;35: 298-9.
166. Steginga SK, Dunn J. Women's experiences following treatment for gynecologic cancer. Oncology Nursing Forum 1997;24:1403-8.
167. Kornblith AB, Thaler HT, Wong G, et al. Quality of life of women with ovarian cancer. Gynecol Oncol 1995;59:231-42.
168. Portenoy RK, Kornblith AB, Wong G, et al. Pain in ovarian cancer patients. Prevalence, characteristics, and associated symptoms. Cancer 1994;74:907-15.
169. Zech D, Grond S, Lynch J, et al. Validation of the World Health Organisation guidelines for cancer pain relief: a 10-year prospective study. Pain 1995;63:65-76.
170. Agency for Health Care Policy and Research. Management of cancer pain. Rockville, MD: Agency for Health Care Policy and Research, 1994.
171. Tunca JC, Buchler DA, Mack EA, et al. The management of ovarian-cancer-caused bowel obstruction. Gynecol Oncol 1981;12:186-92.
172. Rubin SC, Hoskins WJ, Benjamin I, et al. Palliative surgery for intestinal obstruction in advanced ovarian cancer. Gynecol Oncol 1989;34:16-19.
173. Redman CW, Shafi MI, Ambrose S, et al. Survival following intestinal obstruction in ovarian cancer. Eur J Surg Oncol 1988;14:383-6.
174. Zoetmulder FA, Helmerhorst TJ, van Coevorden F, et al. Management of bowel obstruction in patients with advanced ovarian cancer. Eur J Cancer 1994;30A:1625-8.
175. Clarke-Pearson DL, Chin NO, DeLong ER, et al. Surgical management of intestinal obstruction in ovarian cancer. I. Clinical features, postoperative complications, and survival. Gynecol Oncol 1987;26:11-8.
176. Krebs HB, Goplerud DR. Surgical management of bowel obstruction in advanced ovarian carcinoma. Obstet Gynecol 1983;61:327-30.
177. Beard SM, Coleman R, Radford J, et al. The use of cisplatin and paclitaxel as a first line treatment in ovarian cancer. Sheffield: Trent Institute for Health Services Research, 1997.
178. Beard SM, Coleman RE, Radford J, et al. Supplementary document: The use of paclitaxel in the first line treatment of ovarian cancer. Sheffield: Trent Institute for Health Services Research, in press.